Apellis Pharmaceuticals Inc (APLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2019 | 09-2019 | 06-2019 | 03-2019 | 12-2018 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -304,707 | -191,489 | -121,665 | -50,574 | -127,502 |
| Depreciation Amortization | 2,938 | 769 | 378 | 218 | 582 |
| Accounts payable and accrued liabilities | -1,641 | 1,792 | 3,801 | 1,906 | -978 |
| Other Working Capital | 53,150 | 36,015 | 26,030 | 8,274 | -12,126 |
| Other Operating Activity | 39,125 | 23,849 | 15,989 | 4,616 | 8,783 |
| Operating Cash Flow | $-211,135 | $-129,064 | $-75,467 | $-35,560 | $-131,241 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -1,693 | -1,538 | -1,067 | -875 | N/A |
| Investing Cash Flow | $-1,693 | $-1,538 | $-1,067 | $-875 | $N/A |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 212,912 | 213,400 | N/A | N/A | N/A |
| Debt Repayment | -28,701 | -28,701 | -21,701 | -21,701 | N/A |
| Common Stock Issued | 112,710 | 112,013 | 111,083 | 110,119 | 131,921 |
| Other Financing Activity | 91,620 | 91,620 | 100,000 | 60,000 | -18 |
| Financing Cash Flow | $388,541 | $388,332 | $189,382 | $148,418 | $131,903 |
| Exchange Rate Effect | 4 | -3 | 12 | -4 | -38 |
| Beginning Cash Position | 176,268 | 176,268 | 176,268 | 176,268 | 175,644 |
| End Cash Position | 351,985 | 433,995 | 289,128 | 288,247 | 176,268 |
| Net Cash Flow | $175,717 | $257,727 | $112,860 | $111,979 | $624 |
| Free Cash Flow | |||||
| Operating Cash Flow | -211,135 | -129,064 | -75,467 | -35,560 | -131,241 |
| Capital Expenditure | -1,693 | -1,538 | -1,067 | -875 | N/A |
| Free Cash Flow | -212,828 | -130,602 | -76,534 | -36,435 | -131,241 |